Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 06, 2022 03:01 ET
|
Mainz BioMed NV
ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000...
Interventional Oncology Global Market Report 2022: Favourable Government Policies and Technological Advancements Drive Sector
December 02, 2022 08:28 ET
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market By Product: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ...
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 29, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Oncology Precision Medicine Market Report 2022: Featuring Novartis, F. Hoffmann-La Roche, Merck & Co, Quest Diagnostics & More
November 23, 2022 08:08 ET
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 By Ecosystem, By Application and By...
Florida Cancer Specialists & Research Institute Supports American Cancer Society Guidelines for Colonoscopies
November 22, 2022 08:00 ET
|
Florida Cancer Specialists & Research Institute
Ft. Myers, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) takes exception to a recent study published in the New England Journal of...
Florida Cancer Specialists & Research Institute Supports American Cancer Society Guidelines for Colonoscopies
November 22, 2022 08:00 ET
|
Florida Cancer Specialists & Research Institute
Ft. Myers, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) takes exception to a recent study published in the New England Journal of...
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 22, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 15, 2022 08:00 ET
|
Mainz BioMed NV
eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023Enhances ColoFuture’s demographic profile and expedites data read-out timelinePotential to identify advanced adenomas, a...
Cancer Monoclonal Antibodies Market Is A $108.47 Billion Opportunity; Successful Cancer Therapeutic Strategies
November 10, 2022 07:02 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Worldwide Cancer Monoclonal Antibodies Market size in 2021 was USD 51.88 billion and will be worth USD 108.47 billion with an 8.54% CAGR. A...
Mainz Biomed Provides Third Quarter 2022 Update
November 02, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...